

# Lars Rejnmark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3426069/publications.pdf>

Version: 2024-02-01

213  
papers

11,615  
citations

30551

56  
h-index

37326

100  
g-index

216  
all docs

216  
docs citations

216  
times ranked

12399  
citing authors

#	ARTICLE	IF	CITATIONS
1	C-11 methionine positron emission tomography scans improve the preoperative localization of pathologic parathyroid glands in primary hyperparathyroidism. <i>Scandinavian Journal of Surgery</i> , 2022, 111, 145749692110368.	1.3	2
2	PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e372-e385.	1.8	23
3	The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal women. <i>Clinical Endocrinology</i> , 2022, 96, 812-818.	1.2	2
4	The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: a nationwide historic cohort study. <i>BMC Endocrine Disorders</i> , 2022, 22, 14.	0.9	3
5	Opportunities for biomineralization research using multiscale computed X-ray tomography as exemplified by bone imaging. <i>Journal of Structural Biology</i> , 2022, 214, 107822.	1.3	13
6	Effect of Daily Vitamin D3 Supplementation on Muscle Health: An Individual Participant Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1317-1327.	1.8	5
7	European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). <i>European Journal of Endocrinology</i> , 2022, 186, R33-R63.	1.9	73
8	Cardiovascular consequences of parathyroid disorders in adults. <i>Annales D'Endocrinologie</i> , 2021, 82, 151-157.	0.6	12
9	The Calcium-Sensing Receptor Is Essential for Calcium and Bicarbonate Sensitivity in Human Spermatozoa. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1775-1792.	1.8	12
10	Adipocyte-induced transdifferentiation of osteoblasts and its potential role in age-related bone loss. <i>PLoS ONE</i> , 2021, 16, e0245014.	1.1	9
11	Lower Leg Arterial Calcifications Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Hypoparathyroid and Pseudohypoparathyroid Patients. <i>Calcified Tissue International</i> , 2021, 108, 775-784.	1.5	5
12	Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 297-316.	2.6	25
13	Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 1876-1888.	1.3	22
14	Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 1946-1957.	1.3	19
15	Determinants of hypercalciuria and renal calcifications in chronic hypoparathyroidism: A cross-sectional study. <i>Clinical Endocrinology</i> , 2021, 95, 286-294.	1.2	8
16	Change in Estimated Glomerular Filtration Rate in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1-84) Compared With a Historical Control Cohort. <i>Journal of the Endocrine Society</i> , 2021, 5, A257-A258.	0.1	2
17	TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension. <i>Journal of the Endocrine Society</i> , 2021, 5, A253-A253.	0.1	0
18	Vitamin D and Muscle Health: A Systematic Review and Metaanalysis of Randomized Placebo-Controlled Trials. <i>Journal of the Endocrine Society</i> , 2021, 5, A281-A281.	0.1	1

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Events in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1-84) Compared With a Historical Control Cohort. <i>Journal of the Endocrine Society</i> , 2021, 5, A257-A257.	0.1	1
20	Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1-84) Compared With a Historical Control Cohort. <i>Journal of the Endocrine Society</i> , 2021, 5, A267-A267.	0.1	1
21	Serum Calcium Levels in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1-84) Compared With a Historical Control Cohort. <i>Journal of the Endocrine Society</i> , 2021, 5, A268-A268.	0.1	0
22	Changes in treatment needs for chronic postoperative hypoparathyroidism during initiation of conventional treatment compared to stable phase of treatment. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00269.	1.0	0
23	Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 4246-4257.	1.3	15
24	3-Hydroxybutyrate administration elevates plasma parathyroid hormone in a pilot human randomized, controlled, cross over trial. <i>Bone</i> , 2021, 153, 116166.	1.4	1
25	The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. <i>BMC Endocrine Disorders</i> , 2021, 21, 232.	0.9	3
26	Endocrine Disorders with Parathyroid Hormone-Independent Hypercalcemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 711-720.	1.2	3
27	25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 699-708.	1.1	19
28	Effects of Supplemental Vitamin D on Muscle Performance and Quality of Life in Graves' Disease: A Randomized Clinical Trial. <i>Thyroid</i> , 2020, 30, 661-671.	2.4	17
29	Dental anomalies and orthodontic characteristics in patients with pseudohypoparathyroidism. <i>BMC Oral Health</i> , 2020, 20, 2.	0.8	9
30	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. <i>Hormone Research in Paediatrics</i> , 2020, 93, 182-196.	0.8	42
31	SAT-399 Baseline Characteristics from the Observational PARADIGHM Registry of Patients with Chronic Hypoparathyroidism. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
32	Circulating Levels of Muscle-Related Metabolites Increase in Response to a Daily Moderately High Dose of a Vitamin D3 Supplement in Women with Vitamin D Insufficiency—Secondary Analysis of a Randomized Placebo-Controlled Trial. <i>Nutrients</i> , 2020, 12, 1310.	1.7	8
33	Milk protein complexation enhances post prandial vitamin D <sub>3</sub> absorption in rats. <i>Food and Function</i> , 2020, 11, 4953-4959.	2.1	7
34	Mapping the 3D orientation of nanocrystals and nanostructures in human bone: Indications of novel structural features. <i>Science Advances</i> , 2020, 6, eaba4171.	4.7	51
35	Effects of PTH and PTH Hypersecretion on Bone: a Clinical Perspective. <i>Current Osteoporosis Reports</i> , 2020, 18, 103-114.	1.5	25
36	Changes in treatment needs of hypoparathyroidism during pregnancy and lactation: A case series. <i>Clinical Endocrinology</i> , 2020, 93, 261-268.	1.2	19

#	ARTICLE	IF	CITATIONS
37	Vitamin D and Muscle Health: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1651-1660.	3.1	35
38	ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of calcium metabolic disorders and osteoporosis. <i>European Journal of Endocrinology</i> , 2020, 183, G57-G65.	1.9	33
39	Renal Complications in Hypoparathyroidism. , 2020, , 99-108.		0
40	Arterial Stiffness and Blood Pressure in Patients Newly Diagnosed with Gravesâ€™ Disease Compared with Euthyroid Controls. <i>European Thyroid Journal</i> , 2020, 9, 148-156.	1.2	5
41	Benefits of 11C-methionine PET/MRI and intraoperative fluorescence in treating hyperparathyroidism. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.2	0
42	SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	3
43	Vitamin D and the risk of dystocia: A case-control study. <i>PLoS ONE</i> , 2020, 15, e0240406.	1.1	6
44	Vitamin D and the risk of dystocia: A case-control study. , 2020, 15, e0240406.		0
45	Vitamin D and the risk of dystocia: A case-control study. , 2020, 15, e0240406.		0
46	Vitamin D and the risk of dystocia: A case-control study. , 2020, 15, e0240406.		0
47	Vitamin D and the risk of dystocia: A case-control study. , 2020, 15, e0240406.		0
48	Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT). <i>European Journal of Endocrinology</i> , 2019, 181, P1-P19.	1.9	61
49	Effect of 9 months of vitamin D supplementation on arterial stiffness and blood pressure in Gravesâ€™ disease: a randomized clinical trial. <i>Endocrine</i> , 2019, 66, 386-397.	1.1	11
50	Expanding the spectrum of genetic variants in the calciumâ€™sensing receptor ( CASR ) gene in hypercalcemic individuals. <i>Clinical Endocrinology</i> , 2019, 91, 683-690.	1.2	2
51	Effects of Elevated Parathyroid Hormone Levels on Muscle Health, Postural Stability and Quality of Life in Vitamin D-Insufficient Healthy Women: A Cross-Sectional Study. <i>Calcified Tissue International</i> , 2019, 105, 642-650.	1.5	14
52	Managing vitamin D deficiency in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2019, 10, 394-400.	0.9	42
53	Effect of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3223-3232.	1.8	40
54	Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. <i>Nature Reviews Nephrology</i> , 2019, 15, 435-455.	4.1	318

#	ARTICLE	IF	CITATIONS
55	Muscle Performance and Postural Stability Are Reduced in Patients with Newly Diagnosed Graves' Disease. <i>Thyroid</i> , 2019, 29, 783-789.	2.4	8
56	25(OH)D3 and 1.25(OH)2D3 inhibits TNF- $\alpha$ expression in human monocyte derived macrophages. <i>PLoS ONE</i> , 2019, 14, e0215383.	1.1	15
57	T-score differences and nonprogression in lumbar vertebrae as predictors of vertebral fractures. <i>Clinical Endocrinology</i> , 2019, 91, 58-62.	1.2	1
58	Huge variations in definition and reported incidence of postsurgical hypoparathyroidism: a systematic review. <i>Endocrine</i> , 2019, 64, 176-183.	1.1	43
59	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. <i>European Journal of Endocrinology</i> , 2019, 180, P1-P22.	1.9	81
60	Cardiovascular findings in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism: A cohort study. <i>Clinical Endocrinology</i> , 2019, 90, 592-600.	1.2	10
61	Effect of Genetically Low 25-Hydroxyvitamin D on Mortality Risk: Mendelian Randomization Analysis in 3 Large European Cohorts. <i>Nutrients</i> , 2019, 11, 74.	1.7	30
62	Bone Microstructure in Response to Vitamin D3 Supplementation: A Randomized Placebo-Controlled Trial. <i>Calcified Tissue International</i> , 2019, 104, 160-170.	1.5	20
63	Health-related quality of life improves 1 year after parathyroidectomy in primary hyperparathyroidism: A prospective cohort study. <i>Clinical Endocrinology</i> , 2019, 90, 184-191.	1.2	38
64	MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. <i>European Journal of Endocrinology</i> , 2019, 180, R37-R44.	1.9	41
65	MON-526 Risk of Cardiovascular (CV) Conditions in Patients with Chronic Hypoparathyroidism (HypoPT). <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
66	Milk Products in the Treatment of Hypophosphatemic Rickets: A Pilot Study. <i>International Journal of Endocrinology and Metabolism</i> , 2019, 17, e91454.	0.3	0
67	Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 742-752.	0.6	67
68	Non-parathyroid hypercalcemia associated with paraffin oil injection in 12 younger male bodybuilders: a case series. <i>European Journal of Endocrinology</i> , 2018, 178, K29-K37.	1.9	17
69	Bioavailable Testosterone Is Positively Associated With Bone Mineral Density in Male Kidney Transplantation Candidates. <i>Kidney International Reports</i> , 2018, 3, 661-670.	0.4	9
70	Long-Term Complications in Patients With Hypoparathyroidism Evaluated by Biochemical Findings: A Case-Control Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 822-831.	3.1	82
71	Quality of life in hypoparathyroidism. <i>Endocrine</i> , 2018, 59, 237-238.	1.1	13
72	Bone Status Among Patients With Nonsurgical Hypoparathyroidism, Autosomal Dominant Hypocalcaemia, and Pseudohypoparathyroidism: A Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 467-477.	3.1	16

#	ARTICLE	IF	CITATIONS
73	Bone responses to chronic treatment of adult hypoparathyroid patients with PTH peptides. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 3, 51-60.	0.6	0
74	Predictors of Renal Function and Calcifications in Primary Hyperparathyroidism: A Nested Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3574-3583.	1.8	27
75	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. <i>Nature Reviews Endocrinology</i> , 2018, 14, 476-500.	4.3	224
76	Effects of Vitamin D3 Supplementation on Muscle Strength, Mass, and Physical Performance in Women with Vitamin D Insufficiency: A Randomized Placebo-Controlled Trial. <i>Calcified Tissue International</i> , 2018, 103, 483-493.	1.5	47
77	Dental Findings in Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism: A Systematic Review. <i>Frontiers in Physiology</i> , 2018, 9, 701.	1.3	12
78	Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper. <i>Frontiers in Endocrinology</i> , 2018, 9, 373.	1.5	249
79	The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial. <i>Endocrine</i> , 2018, 62, 182-194.	1.1	18
80	Pro-FHH: A Risk Equation to Facilitate the Diagnosis of Parathyroid-Related Hypercalcemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2534-2542.	1.8	34
81	Prevalence and Risk of Vertebral Fractures in Primary Hyperparathyroidism: A Nested Case-Control Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1657-1664.	3.1	27
82	Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial. <i>Clinical Endocrinology</i> , 2018, 89, 656-666.	1.2	10
83	Effect of calcium citrate vs calcium carbonate on elevated parathyroid hormone after Roux-Y gastric bypass. A double-blind, randomized trial. <i>Clinical Endocrinology</i> , 2018, 89, 734-741.	1.2	10
84	Effects of vitamin D supplementation on markers for cardiovascular disease and type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. <i>American Journal of Clinical Nutrition</i> , 2018, 107, 1043-1053.	2.2	49
85	Hypoparathyroidism. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17055.	18.1	142
86	AP2S1 and GNA11 mutations are not a common cause of familial hypocalciuric hypercalcemia. <i>European Journal of Endocrinology</i> , 2017, 176, 177-185.	1.9	22
87	Current Assays to Determine Free 25-Hydroxyvitamin D in Serum. <i>Journal of AOAC INTERNATIONAL</i> , 2017, 100, 1323-1327.	0.7	23
88	Vitamin D and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. <i>PLoS ONE</i> , 2017, 12, e0170791.	1.1	219
89	Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study. <i>BMC Nephrology</i> , 2017, 18, 284.	0.8	33
90	Non-skeletal health effects of vitamin D supplementation: A systematic review on findings from meta-analyses summarizing trial data. <i>PLoS ONE</i> , 2017, 12, e0180512.	1.1	189

#	ARTICLE	IF	CITATIONS
91	Recurrence of Hyperparathyroid Hypercalcemia in a Patient With the HRPT-2 Mutation and a Previous Parathyroid Carcinoma in Hyperparathyroidism-Jaw Tumor Syndrome. <i>International Journal of Endocrinology and Metabolism</i> , 2016, 14, e35424.	0.3	12
92	Correlations Between Changes in Undercarboxylated Osteocalcin and Muscle Function in Hypoparathyroidism. <i>International Journal of Endocrinology and Metabolism</i> , 2016, 14, e38440.	0.3	7
93	Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1440-1448.	3.1	77
94	Pseudohypoparathyroidism "epidemiology, mortality and risk of complications. <i>Clinical Endocrinology</i> , 2016, 84, 904-911.	1.2	61
95	Effect of Intravenous Contrast on Volumetric Bone Mineral Density in Patients with Chronic Kidney Disease. <i>Journal of Clinical Densitometry</i> , 2016, 19, 423-429.	0.5	7
96	Arterial Stiffness and Central Hemodynamics in Thyroidectomized Patients on Long-Term Substitution Therapy with Levothyroxine. <i>Thyroid</i> , 2016, 26, 779-784.	2.4	5
97	High Level of Agreement between Electronic and Paper Mode of Administration of a Thyroid-Specific Patient-Reported Outcome, ThyPRO. <i>European Thyroid Journal</i> , 2016, 5, 65-72.	1.2	16
98	The cardiovascular system in familial hypocalciuric hypercalcemia: a cross-sectional study on physiological effects of inactivating variants in the calcium-sensing receptor gene. <i>European Journal of Endocrinology</i> , 2016, 175, 299-309.	1.9	7
99	Multiple endocrine neoplasia phenocopy revealed as a co-occurring neuroendocrine tumor and familial hypocalciuric hypercalcemia type 3. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 922-927.	0.2	2
100	Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: A randomized placebo-controlled trial. <i>Clinical Endocrinology</i> , 2016, 84, 342-347.	1.2	67
101	Management of Hypoparathyroidism: Present and Future. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2313-2324.	1.8	151
102	Vitamin D content in human breast milk: a 9-mo follow-up study. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 107-114.	2.2	85
103	Association between bone indices assessed by DXA, HR-pQCT and QCT scans in post-menopausal women. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 638-645.	1.3	55
104	Inverse Correlation at the Hip Between Areal Bone Mineral Density Measured by Dual-Energy X-ray Absorptiometry and Cortical Volumetric Bone Mineral Density Measured by Quantitative Computed Tomography. <i>Journal of Clinical Densitometry</i> , 2016, 19, 226-233.	0.5	10
105	The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1738-1744.	3.1	182
106	The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial. <i>Nutrition Journal</i> , 2015, 14, 102.	1.5	43
107	Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial. <i>Journal of Pineal Research</i> , 2015, 59, 221-229.	3.4	103
108	Hypoparathyroidism: Replacement Therapy with Parathyroid Hormone. <i>Endocrinology and Metabolism</i> , 2015, 30, 436.	1.3	17

#	ARTICLE	IF	CITATIONS
109	Bone Indices in Thyroidectomized Patients on Long-Term Substitution Therapy with Levothyroxine Assessed by DXA and HR-pQCT. <i>Journal of Thyroid Research</i> , 2015, 2015, 1-9.	0.5	10
110	No beneficial effects of vitamin D supplementation on muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2015, 172, 609-617.	1.9	23
111	The Effect of Treatment With PTH on Undercarboxylated Osteocalcin and Energy Metabolism in Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2758-2762.	1.8	18
112	European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. <i>European Journal of Endocrinology</i> , 2015, 173, G1-G20.	1.9	326
113	Relationship Between Aldosterone and Parathyroid Hormone, and the Effect of Angiotensin and Aldosterone Inhibition on Bone Health. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2015, 13, 194-205.	1.3	7
114	Causes of Vitamin D Deficiency and Effect of Vitamin D Supplementation on Metabolic Complications in Obesity: a Review. <i>Current Obesity Reports</i> , 2015, 4, 429-440.	3.5	43
115	The Effects of Calcium Supplementation on Verified Coronary Heart Disease Hospitalization and Death in Postmenopausal Women: A Collaborative Meta-Analysis of Randomized Controlled Trials. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 165-175.	3.1	131
116	Conventional Treatment of Chronic Hypoparathyroidism. , 2015, , 303-312.		0
117	Post-operative parathyroid hormone can be used as a predictor of normocalcaemia after total thyroidectomy. <i>Danish Medical Journal</i> , 2015, 62, A5157.	0.5	4
118	Three-Year Successful Cinacalcet Treatment of Secondary Hyperparathyroidism in a Patient with X-Linked Dominant Hypophosphatemic Rickets: A Case Report. <i>Case Reports in Endocrinology</i> , 2014, 2014, 1-5.	0.2	10
119	Therapy of Hypoparathyroidism by Replacement with Parathyroid Hormone. <i>Scientifica</i> , 2014, 2014, 1-8.	0.6	6
120	Muscle Function Is Impaired in Patients With "Asymptomatic" Primary Hyperparathyroidism. <i>World Journal of Surgery</i> , 2014, 38, 549-557.	0.8	19
121	Vitamin D Treatment in Primary Hyperparathyroidism: A Randomized Placebo Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1072-1080.	1.8	155
122	Effects on Calcium Homeostasis of Changing PTH Replacement Therapy of Postoperative Hypoparathyroidism from Intact PTH to Teriparatide: A Case Series. <i>Calcified Tissue International</i> , 2014, 95, 374-381.	1.5	2
123	Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3580-3594.	1.8	318
124	Effects of 12weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency " a double-blind, randomized, placebo-controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1115-1124.	1.5	113
125	Increased Trabecular Volumetric Bone Mass Density in Familial Hypocalciuric Hypercalcemia (FHH) Type 1: A Cross-Sectional Study. <i>Calcified Tissue International</i> , 2014, 95, 141-152.	1.5	16
126	Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> ,the, 2014, 2, 719-729.	5.5	319



#	ARTICLE	IF	CITATIONS
127	Postsurgical Hypoparathyroidism—Risk of Fractures, Psychiatric Diseases, Cancer, Cataract, and Infections. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2504-2510.	3.1	196
128	The Effect of High-Dose Vitamin D Supplementation on Calcitropic Hormones and Bone Mineral Density in Obese Subjects with Low Levels of Circulating 25-Hydroxyvitamin D: Results from a Randomized Controlled Study. <i>Calcified Tissue International</i> , 2013, 93, 69-77.	1.5	41
129	BMD improvements after operation for primary hyperparathyroidism. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 113-120.	0.8	25
130	The Pathogenesis, Treatment and Prevention of Osteoporosis in Men. <i>Drugs</i> , 2013, 73, 15-29.	4.9	35
131	Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow-up study. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2277-2285.	3.1	235
132	Cobalamin and haptocorrin in human milk and cobalamin-related variables in mother and child: a 9-mo longitudinal study. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 389-395.	2.2	65
133	Further Insights into the Pathogenesis of Primary Hyperparathyroidism: A Nested Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 87-96.	1.8	34
134	Fracture risk after initiation of antihypertensive therapy. <i>Nature Reviews Endocrinology</i> , 2013, 9, 189-190.	4.3	3
135	Muscle function and quality of life are not impaired in familial hypocalciuric hypercalcemia: a cross-sectional study on physiological effects of inactivating variants in the calcium-sensing receptor gene (CASR). <i>European Journal of Endocrinology</i> , 2013, 169, 349-357.	1.9	14
136	PTH(1-84) replacement therapy in hypoparathyroidism: A randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2232-2243.	3.1	69
137	Recombinant hormones in osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1135-1147.	1.4	1
138	No effect of season of birth on risk of type 1 diabetes, cancer, schizophrenia and ischemic heart disease, while some variations may be seen for pneumonia and multiple sclerosis. <i>Dermato-Endocrinology</i> , 2013, 5, 309-316.	1.9	6
139	Increased Plasma Concentrations of Vitamin D Metabolites and Vitamin D Binding Protein in Women Using Hormonal Contraceptives: A Cross-Sectional Study. <i>Nutrients</i> , 2013, 5, 3470-3480.	1.7	64
140	Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. <i>BMJ, The</i> , 2012, 345, e6409-e6409.	3.0	555
141	Vitamin D deficiency in postmenopausal, healthy women predicts increased cardiovascular events: a 16-year follow-up study. <i>European Journal of Endocrinology</i> , 2012, 167, 553-560.	1.9	35
142	Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): A randomized controlled study. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 781-788.	3.1	67
143	Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2670-2681.	1.8	186
144	Oral Bisphosphonate Use Increases the Risk for Inflammatory Jaw Disease: A Cohort Study. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012, 70, 821-829.	0.5	29

#	ARTICLE	IF	CITATIONS
145	Determinants of plasma PTH and their implication for defining a reference interval. <i>Clinical Endocrinology</i> , 2011, 74, 37-43.	1.2	54
146	Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls – a cross-sectional study. <i>Clinical Endocrinology</i> , 2011, 74, 130-136.	1.2	17
147	Effects of vitamin D on muscle function and performance: a review of evidence from randomized controlled trials. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 25-37.	1.1	121
148	Are Antiresorptive Drugs Effective Against Fractures in Patients with Diabetes?. <i>Calcified Tissue International</i> , 2011, 88, 209-214.	1.5	107
149	Increased Fracture Risk in Normocalcemic Postmenopausal Women with High Parathyroid Hormone Levels: A 16-Year Follow-Up Study. <i>Calcified Tissue International</i> , 2011, 88, 238-245.	1.5	53
150	The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2358-2370.	3.1	158
151	Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2317-2337.	3.1	485
152	New and Emerging Antiresorptive Treatments in Osteoporosis. <i>Current Drug Safety</i> , 2011, 6, 75-88.	0.3	17
153	Emerging Anabolic Treatments in Osteoporosis. <i>Current Drug Safety</i> , 2011, 6, 62-74.	0.3	34
154	Patients with surgically cured primary hyperparathyroidism have a reduced quality of life compared with population-based healthy sex-, age-, and season-matched controls. <i>European Journal of Endocrinology</i> , 2011, 165, 753-760.	1.9	29
155	Nephrolithiasis and Renal Calcifications in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2377-2385.	1.8	158
156	PTH Treatment in Hypoparathyroidism. <i>Current Drug Safety</i> , 2011, 6, 89-99.	0.3	22
157	High-Dose Treatment With Vitamin A Analogues and Risk of Fractures. <i>Archives of Dermatology</i> , 2010, 146, 478-82.	1.7	34
158	Gastric and Esophagus Events Before and During Treatment of Osteoporosis. <i>Calcified Tissue International</i> , 2010, 86, 110-115.	1.5	40
159	Risk of Atrial Fibrillation Associated with Use of Bisphosphonates and Other Drugs Against Osteoporosis: A Cohort Study. <i>Calcified Tissue International</i> , 2010, 86, 335-342.	1.5	29
160	Effects of Smoking on Severity of Disease in Primary Hyperparathyroidism. <i>Calcified Tissue International</i> , 2010, 87, 406-413.	1.5	9
161	Simvastatin Does Not Affect Vitamin D Status, but Low Vitamin D Levels Are Associated with Dyslipidemia: Results from a Randomised, Controlled Trial. <i>International Journal of Endocrinology</i> , 2010, 2010, 1-6.	0.6	56
162	Use of Organic Nitrates and the Risk of Hip Fracture: A Population-Based Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1924-1931.	1.8	41

#	ARTICLE	IF	CITATIONS
163	Bone Involvement in Primary Hyperparathyroidism and Changes After Parathyroidectomy. <i>European Endocrinology</i> , 2010, 10, 84.	0.8	19
164	Loss of life years after a hip fracture. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2009, 80, 525-530.	1.2	35
165	Fracture risk in patients with different types of cancer. <i>Acta Oncologica</i> , 2009, 48, 105-115.	0.8	32
166	Reduced Prediagnostic 25-Hydroxyvitamin D Levels in Women with Breast Cancer: A Nested Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2655-2660.	1.1	57
167	Diabetes and Its Complications and Their Relationship with Risk of Fractures in Type 1 and 2 Diabetes. <i>Calcified Tissue International</i> , 2009, 84, 45-55.	1.5	224
168	Hypertension Is a Risk Factor for Fractures. <i>Calcified Tissue International</i> , 2009, 84, 103-111.	1.5	121
169	Osteoarthritis and Risk of Fractures. <i>Calcified Tissue International</i> , 2009, 84, 249-256.	1.5	41
170	Skeletal consequences of familial hypocalciuric hypercalcaemia vs. primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 2009, 71, 798-807.	1.2	44
171	Hip Fracture Patients at Risk of Second Hip Fracture: A Nationwide Population-Based Cohort Study of 169,145 Cases During 1977-2001. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1299-1307.	3.1	242
172	Anxiolytics and Sedatives and Risk of Fractures: Effects of Half-life. <i>Calcified Tissue International</i> , 2008, 82, 34-43.	1.5	34
173	Selective Serotonin Reuptake Inhibitors and Other Antidepressants and Risk of Fracture. <i>Calcified Tissue International</i> , 2008, 82, 92-101.	1.5	84
174	Fracture Risk Associated with Different Types of Oral Corticosteroids and Effect of Termination of Corticosteroids on the Risk of Fractures. <i>Calcified Tissue International</i> , 2008, 82, 249-257.	1.5	68
175	Effect of Tamoxifen and Aromatase Inhibitors on the Risk of Fractures in Women with Breast Cancer. <i>Calcified Tissue International</i> , 2008, 82, 334-340.	1.5	41
176	Parathyroid response to vitamin D insufficiency: relations to bone, body composition and to lifestyle characteristics. <i>Clinical Endocrinology</i> , 2008, 69, 29-35.	1.2	37
177	Pre-existing diseases and use of loop diuretics may explain increased mortality in secondary hyperparathyroidism. <i>Clinical Endocrinology</i> , 2008, 69, 514-514.	1.2	0
178	Are fractures due to anticoagulants or the disease necessitating the treatment?. <i>International Journal of Cardiology</i> , 2008, 127, 423-424.	0.8	2
179	Intake of vitamin D and risk of breast cancer - A meta-analysis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 111, 195-199.	1.2	72
180	Fracture risk in very young women using combined oral contraceptives. <i>Contraception</i> , 2008, 78, 358-364.	0.8	20

#	ARTICLE	IF	CITATIONS
181	The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. <i>Contraception</i> , 2008, 78, 459-464.	0.8	47
182	Plasma 1,25(OH)2D levels decrease in postmenopausal women with hypovitaminosis D.. <i>European Journal of Endocrinology</i> , 2008, 158, 571-576.	1.9	27
183	Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. <i>European Journal of Endocrinology</i> , 2008, 159, 719-727.	1.9	44
184	Cardiovascular Drugs and Bone. <i>Current Drug Safety</i> , 2008, 3, 178-184.	0.3	10
185	Bone Effects of Glitazones and Other Anti-Diabetic Drugs. <i>Current Drug Safety</i> , 2008, 3, 194-198.	0.3	18
186	Fracture Risk in Patients With Chronic Lung Diseases Treated With Bronchodilator Drugs and Inhaled and Oral Corticosteroids. <i>Chest</i> , 2007, 132, 1599-1607.	0.4	66
187	Fracture risk in users of oral anticoagulants: A nationwide case-control study. <i>International Journal of Cardiology</i> , 2007, 118, 338-344.	0.8	55
188	Has Mortality After a Hip Fracture Increased?. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1720-1726.	1.3	83
189	Fracture Risk Associated with Parkinsonism and Anti-Parkinson Drugs. <i>Calcified Tissue International</i> , 2007, 81, 153-161.	1.5	75
190	Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. <i>Thrombosis and Haemostasis</i> , 2007, 97, 234-239.	1.8	7
191	Oral contraceptive use and risk of fractures. <i>Contraception</i> , 2006, 73, 571-576.	0.8	34
192	Fracture reducing potential of hormone replacement therapy on a population level. <i>Maturitas</i> , 2006, 54, 285-293.	1.0	13
193	Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: Results from the Danish Osteoporosis Prevention Study (DOPS). <i>Thrombosis and Haemostasis</i> , 2006, 95, 915-916.	1.8	4
194	Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. <i>Journal of Hypertension</i> , 2006, 24, 581-589.	0.3	183
195	Decreased Fracture Risk in Users of Organic Nitrates: A Nationwide Case-Control Study. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 1811-1817.	3.1	66
196	Ten-year prediction of osteoporosis from baseline bone mineral density: development of prognostic thresholds in healthy postmenopausal women. The Danish Osteoporosis Prevention Study. <i>Osteoporosis International</i> , 2006, 17, 245-251.	1.3	17
197	Socioeconomic aspects of fractures within universal public healthcare: A nationwide case-control study from Denmark. <i>Scandinavian Journal of Public Health</i> , 2006, 34, 371-377.	1.2	57
198	Loop Diuretics Increase Bone Turnover and Decrease BMD in Osteopenic Postmenopausal Women: Results From a Randomized Controlled Study With Bumetanide. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 163-170.	3.1	96

#	ARTICLE	IF	CITATIONS
199	Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. <i>Osteoporosis International</i> , 2005, 16, 134-141.	1.3	184
200	Fracture Risk Associated with Use of Antiepileptic Drugs. <i>Epilepsia</i> , 2004, 45, 1330-1337.	2.6	238
201	Effects of Simvastatin on Bone Turnover and BMD: A 1-Year Randomized Controlled Trial in Postmenopausal Osteopenic Women. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 737-744.	3.1	95
202	Hip fracture risk in statin users? a population-based Danish case-control study. <i>Osteoporosis International</i> , 2004, 15, 452-8.	1.3	86
203	Fracture Risk in Perimenopausal Women Treated with Beta-Blockers. <i>Calcified Tissue International</i> , 2004, 75, 365-372.	1.5	98
204	Smoking as a Risk Factor for Graves' Disease, Toxic Nodular Goiter, and Autoimmune Hypothyroidism. <i>Thyroid</i> , 2002, 12, 69-75.	2.4	104
205	Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. <i>European Journal of Endocrinology</i> , 2002, 146, 635-642.	1.9	72
206	Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case-control study. <i>Clinical Endocrinology</i> , 2002, 56, 159-167.	1.2	80
207	Hip Fracture Prevention. <i>Pharmacoeconomics</i> , 2001, 19, 449-468.	1.7	21
208	Fractures in Patients with Primary Idiopathic Hypothyroidism. <i>Thyroid</i> , 2000, 10, 335-340.	2.4	47
209	Fracture Risk in Patients Treated for Hyperthyroidism. <i>Thyroid</i> , 2000, 10, 341-348.	2.4	72
210	Vitamin D insufficiency and hyperparathyroidism, general health and quality of life - a cross sectional study. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
211	Effect of vitamin D supplementation on cardiovascular indices in Graves' disease. A randomized clinical trial. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
212	Risk of fractures in primary hyperparathyroidism: A systematic review and metaanalysis. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
213	Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study. <i>Advances in Therapy</i> , 0, , .	1.3	0